Manuela Ferracin

An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues.

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.

Familial cancer associated with a polymorphism in ARLTS1.

MicroRNA gene expression deregulation in human breast cancer.

miR-15 and miR-16 induce apoptosis by targeting BCL2.

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

A microRNA expression signature of human solid tumors defines cancer gene targets.

Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.

A microRNA signature of hypoxia.

MicroRNAs in human cancer: from research to therapy.

Regulation of microRNA expression: the hypoxic component.

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Tumor suppressor functions of ARLTS1 in lung cancers.

mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer.

Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas.

Micro-RNA profiling in kidney and bladder cancers.

MiR-15a and miR-16-1 cluster functions in human leukemia.

Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.

MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation.

Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155.

MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.

Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis.

Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4.

Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment.

Modulation of mismatch repair and genomic stability by miR-155.

Micromarkers: miRNAs in cancer diagnosis and prognosis.

Oncogenic role of miR-483-3p at the IGF2/483 locus.

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.

Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.

Altered miRNA expression in T regulatory cells in course of multiple sclerosis.

MicroRNAs dysregulation in human malignant pleural mesothelioma.

Mutated beta-catenin evades a microRNA-dependent regulatory loop.

MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.

MicroRNAs: toward the clinic for breast cancer patients.

Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.

miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs.

CCAT2, a novel non-coding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.

First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.

Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients.

A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines.

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.

microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.

Involvement of the inconstant bursa of the fifth metatarsophalangeal joint in psoriatic arthritis: a clinical and ultrasonographic study.

Identification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology.

OncomiR detection in circulating body fluids: a PDMS microdevice perspective.

Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes.

An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis.

Mesenchymal progenitors aging highlights a miR-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis.

Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries.

MicroRNAs as biomarker of Parkinson disease? Small but mighty.

Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells.

Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.

Absolute quantification of cell-free microRNAs in cancer patients.

Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR.

Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.

MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy--comparison with human epileptic samples.

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.

Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC.

MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.

Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.